Receptor Profile
Receptor Actions
Effect Profile
Curated + 5 ReportsStrong body load with moderate visuals, mild headspace
Tolerance & Pharmacokinetics
drugs.wikiCross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 5 experience reports (5 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 7
Adverse Effects 2
Real-World Dose Distribution
62K DosesFrom 6 individual dose entries
Oral (n=5)
Form / Preparation
Most common forms and preparations reported
Harm Reduction
drugs.wikiIdentity risk: 4‑HO‑PiPT is rare in the unregulated market; mislabeling/substitution is plausible. Use multi‑reagent testing (e.g., Ehrlich should turn positive/purple for indoles) and, where available, lab drug checking before ingestion. Begin with an allergy test (0.5–1 mg). Accurate dosing: employ a calibrated 0.001 g scale; for sub‑10 mg adjustments, consider volumetric dosing to reduce measurement error. Salt form matters: like other 4‑sub tryptamines, fumarate vs HCl/freebase alter mg‑for‑mg potency by roughly 10–25%; do not assume vendor salt form—confirm if possible and adjust doses conservatively. Storage: 4‑hydroxy tryptamines readily oxidize, especially in solution or warm/humid conditions; store dry, airtight, light‑protected, with desiccant, ideally frozen. Avoid long‑term liquid storage. Physiology and bodyload: transient tachycardia, mild BP rise, tremors/shivering, jaw tension, nausea, and thermoregulation changes are reported with related 4‑HO tryptamines; plan set/setting and temperature control. Duration/redosing: the short main phase can tempt redosing; however, tolerance accrues rapidly within hours and later redoses often add bodyload more than quality—if redosing, do so early and modestly or avoid altogether. Mental health: as with classics, use can acutely unmask anxiety or, rarely, precipitate issues in predisposed individuals; defer if unstable. Visual after‑effects and rare HPPD‑like symptoms can occur—space sessions (≥2 weeks) and avoid heavy polysubstance use. Interactions: absolutely avoid MAOIs, lithium, and tramadol due to potentiation/seizure/serotonin‑toxicity risks; be cautious with SSRIs/SNRIs/TCAs, stimulants, dissociatives, and CNS depressants. Safety: do not drive or engage in hazardous tasks until fully baseline (usually next day). Consider a trusted sober sitter for first trials. Seek medical help for red‑flag signs of serotonin toxicity (agitation, hyperthermia, clonus, tremor, diaphoresis).
References
Data Sources
Cited References
- Banister et al. 2023 - Compounds Patent (5-HT2A receptor activity)
- British Columbia Centre on Substance Use 2022 - Drug Checking Report
- Erowid: Experience Reports - 4-HO-PiPT
- Erowid Experience: 'Alien Comfort' (26mg oral)
- Erowid Experience: 'Dazzled and Disoriented' (30mg oral)
- Erowid Experience: 'Pushing the Boundaries' (0.1-40mg intranasal)
- Isomer Design - PiHKAL/TiHKAL Explorer
Drugs.wiki References
- Isomer Design - 4-HO-PIPT profile (PiHKAL.info)
- Bluelight - 4-HO-PiPT 35 mg oral, short intense window
- Bluelight - Reagent reactions for 4‑HO‑PiPT (Ehrlich indole reactivity expectation)
- TripSit - Drug Combinations overview (MAOI/serotonergic cautions)
- Erowid LSD Interactions (lithium & tricyclics: seizures/fugue states)
- Erowid LSD & Antidepressants overview
- PMC review – Tramadol + SSRIs/SNRIs and serotonin syndrome risk
- PubMed review – Avoiding serotonin syndrome with tramadol + SSRIs (CYP2D6)
- Erowid 4‑AcO‑DET primer – instability in solution; storage advice
- Erowid 4‑AcO‑DET degradation article – 4‑HO tryptamines oxidize; store cold/dry
- Erowid 4‑HO‑MET Effects & Duration (tremors, HR/BP, short duration)
- TripSit resource hub – Volumetric Converter tool
- Saferparty.ch – mislabel warnings (4‑AcO‑DMT/4‑HO‑MET sold as psilocybin)
- Hi‑Ground – Where can I get my drugs checked? (AU drug checking flyer)
- Drugs‑Forum – storing/degradation of tryptamines overview